If this box remains here for more than 30 seconds, click this link to try again.
Products & Services ╗
Best Practice Database
Market Research, Analytics and Forecasting ╗ Analytics
Download FREE Excerpt
12 Info Graphics
24 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
The 21st century has seen an explosion in the availability of all types of data, including healthcare, social media and transactional information. Together, these and other types of large and complex data sets have come to be known as Big Data. Many in the pharmaceutical sector have begun to leverage these new sources and tools to generate deeper insights and to speed up their decision-making in a competitive market.
Among the many challenges facing pharma as the sector strives to develop Big Data capabilities are which functions lead and utilize Big Data, what governance system or policies should be in place, what data capabilities will need to grow, and what type of organizations are best to partner with on projects. Best Practices, LLC undertook this study to probe these questions and current trends in the pharmaceutical sector around Big Data and the issues of governance, data capabilities and partnerships.
This study provides Medical, Commercial and HEOR segmented responses on survey questions
Pharmaceutical; Health Care; Biotech; Chemical; Medical Device; Manufacturing; Consumer Products; Diagnostic; Biopharmaceutical; Clinical Research; Laboratories
Merck; Merck Serono; Novartis; Boehringer Ingelheim; Genentech; Teva Pharmaceutical Industries Ltd; Pfizer; Baxter Healthcare; GlaxoSmithKline ; Bayer; Gilead Sciences; Janssen; Lundbeck; Sanofi; Esteve; Daiichi Sankyo; Purdue Pharma; AstraZeneca